Teleflex Expands Portfolio with BIOTRONIK's Vascular Business Acquisition
Deal News | Feb 27, 2025 | Globenewswire
Teleflex Incorporated has entered into an agreement to acquire BIOTRONIK’s Vascular Intervention business for approximately $760 million, subject to customary adjustments and closing conditions. This acquisition aims to invest in the interventional cardiology and peripheral vascular markets, which are valued at around $10 billion. Teleflex plans to incorporate a wide array of BIOTRONIK’s vascular intervention devices into its existing product portfolio, enhancing its presence and capabilities in coronary and peripheral interventions. With this strategic move, Teleflex aims to expand its global footprint in the healthcare sector and increase its geographic revenue diversification, as half of BIOTRONIK's sales are generated in EMEA. This acquisition also positions Teleflex for future growth and innovation, particularly in emerging resorbable scaffold technologies. The financial transaction is expected to be accretive by $0.10 per share in its first year. The acquisition is to be financed through a newly arranged term loan, existing credit facilities, and cash on hand, with foreign currency exposure hedged through derivative contracts.
Sectors
- Medical Devices
- Healthcare
Geography
- United States – The acquiring company, Teleflex, is based in the United States and will be a significant player in the U.S. healthcare market with this acquisition.
- EMEA (Europe, Middle East, Africa) – BIOTRONIK generates a significant portion of its revenues in this region, making it a focal area for the acquisition’s strategic intent.
Industry
- Medical Devices – This industry is relevant due to the focus on vascular intervention devices, which are a key component of the medical technology products offered by both Teleflex and BIOTRONIK.
- Healthcare – The acquisition is centered around improving the offerings in personal interventional healthcare, specifically in cardiology and peripheral interventions.
Financials
- 760 million – Estimated cash payment upon closing the deal, before adjustments.
- 91 million – Expected revenue generation from acquired BIOTRONIK products in Q4 2025.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Teleflex Incorporated | Acquirer | Company | A global provider of medical technologies intending to expand its interventional cardiology portfolio through this acquisition. |
| BIOTRONIK SE & Co. KG | Seller | Company | The company whose Vascular Intervention business is being acquired by Teleflex. |
| Liam Kelly | Chairman, President and CEO | Person | Liam Kelly is leading the strategic acquisition for Teleflex, emphasizing the expansion in the interventional cardiology and peripheral markets. |